InvestorsHub Logo

lucky9

02/21/14 1:45 PM

#561 RE: noretreat #558

Consider the market on psoriasis alone and then consider the rest of autoimmune plus orphan cancers. $150 in two years

Seel

02/21/14 1:57 PM

#562 RE: noretreat #558

ISIS pr'd successful interim trial results today. Supports IDRA's antisense technology platform. I think IDRA is rising on ISIS's coat-tails today. No complaints here!